Vaxigrip

Vaxigrip

vaccine, influenza

Manufacturer:

Sanofi Pasteur
Full Prescribing Info
Contents
Purified split inactivated influenza virus.
Description
Vaxigrip's active substance is influenza virus*, split, inactivated, 1 dose contains antigens equivalent to: Each 0.5-mL Adult Dose: A/California/7/2009 (H1N1) derived strain used NYMC X-179A 15 mcg HA**, A/Perth/16/2009 (H3N2) like strain used NYMC X-187 derived from A/Victoria/210/2009 15 mcg HA**, B/Brisbane/60/2008 15 mcg HA**.
Each 0.5-mL Pediatric Use Dose: A/California/7/2009 (H1N1) derived strain used NYMC X-179A 15 mcg HA**, A/Perth/16/2009 (H3N2) like strain used NYMC X-187 derived from A/Victoria/210/2009 15 mcg HA**, B/Brisbane/60/2008 15 mcg HA**.
Note: * propagated in eggs.
** haemagglutinin.
It also contains the following excipients: Buffer solution containing sodium chloride, dihydrated disodium phosphate, monopotassium phosphate, potassium chloride and water for injection.
Vaxigrip vaccine complies with the WHO recommendations (Northern Hemisphere) for the 2011/2012 season.
Indications/Uses
Prevention of influenza, in adults and in children 6-35 months (pediatric use), particularly in subjects showing a high risk of associated complications.
Immunization is strongly recommended for elderly, weakened patients, patients w/ drepanocytemia & for immunosuppressed patients.
Dosage/Direction for Use
Adult and Children ≥36 months: One 0.5 mL dose.
Children 6-35 months: 0.25 mL dose.
Children Who Have Not Previously Been Vaccinated: A 2nd dose should be given after an interval of at least 4 weeks.
Administration: IM route or deep SC injection. Vaxigrip should be brought to room temperature before use. Shake before use to obtain a uniform suspension.
Administration Rate and Time: Due to the seasonal nature of influenza, it is recommended to perform vaccination against influenza every year, either at the beginning of autumn in temperate countries or at the beginning of the risk period in tropical countries.
Contraindications
Hypersensitivity to purified split inactivated influenza virus or to any of the excipients of Vaxigrip; allergy to eggs, chicken proteins, neomycin, formaldehyde or octoxinol-9.
Febrile illness or acute infection (in such case, it is preferrable to postpone vaccination).
Special Precautions
Caution should be taken if the patient is immunodepressed, allergic or have shown any abnormal reaction following a previous vaccination.
Vaxigrip should never be administered by IV route.
Excipients with Known Effect: Sodium (chloride, dihydrate disodium phosphate form), potassium (chloride, monopotassium phosphate form).
Effect on the Ability to Drive or Operate Machinery: Vaxigrip is unlikely to produce an effect on the ability to drive vehicles and operate machinery.
Use in pregnancy & lactation: Vaxigrip should only be given to pregnant women on medical advice. It may be administered to breastfeeding women.
Use In Pregnancy & Lactation
Vaxigrip should only be given to pregnant women on medical advice. It may be administered to breastfeeding women.
Adverse Reactions
As with all medicinal products, Vaxigrip may cause undesirable effects: Local Reactions: Erythema (redness), swelling, pain, ecchymosis, induration.
Systemic Reactions: Fever, malaise, shivering, fatigue, headaches, sweating, joint and muscular pain.
These reactions usually disappear within 1-2 days without treatment.
Rarely: Neuralgia (pain located along the course of the nerve), paraesthesia (a sensory perception disorder where reactions to touch, pain, heat or movement are affected), convulsions and transient thrombocytopenia (an insufficient amount of platelets, which play an important role in blood clotting).
Allergic reactions leading to shock in rare cases; vasculitis (inflammation of the blood vessels) with transient renal involvement, in very rare cases; neurological disorders eg, encephalomyelitis, neuritis, Guillain-Barre in rare cases as well.
Drug Interactions
The immunological response may be diminished in patients undergoing immunosuppressive treatment.
Caution For Usage
The patient should inform the physician or pharmacist of any ongoing treatment, or if any other medical product, even if nonprescription have been taken recently.
Storage
Store between +2°C to +8°C (in a refrigerator). Protect from light. Do not freeze.
Vaxigrip must not be used in the event of colouring or presence of foreign particles.
ATC Classification
J07BB02 - influenza, inactivated, split virus or surface antigen ; Belongs to the class of influenza viral vaccines.
Presentation/Packing
Vaccine (inj) (syringe) 0.25 mL (susp for inj) x 1's. 0.5 mL x 1's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in